

**DRUG PRIOR AUTHORIZATION COMMITTEE MEETING**  
**September 20, 2012**  
**600 West Main Street, Interpretative Center**  
**Jefferson City, MO 65101**

**Committee Members Present**

Conrad Balcer, D.O.  
Stephen Calloway, RPh  
Pat Bryant, PharmD  
Morgan Sperry, PharmD, (alternate)

**Committee Members Absent**

Laine Young-Walker, M.D.

**MO HealthNet Staff Present:**

Rhonda Driver, RPh, Director of Pharmacy  
Mark Roaseau, RPh, Clinical Pharmacist  
Andrew Haslag, Fiscal & Administrative Manager  
Jenna Twehus, RN  
Matthew McTeer, Medicaid Pharmaceutical Technician  
Allison Lauf, RN  
Angela Wilson, Unit Supervisor  
Ashley Wilson, Medicaid Pharmaceutical Technician  
Suzanne Glazer  
Marsha Kelly, Clerical  
Jennifer Willmeno, Clerical  
Tasia Roberts, Clerical

**Contractors in Attendance:**

Rick Pope, PharmD, First Health Services  
Jennifer Kemp-Cornelius, PharmD, Xerox  
Josh Moore, Xerox  
Katie Wilbers, Xerox

**Others Attending:**

Lon Lowrey, Novartis	Mike Krug, Sunovion	Mike Donze, Boehringer-Ingelheim	Jeff Knappen, Allergan
John Mattson, Teva	Bruce Valentine, Acorda Therapeutics	Stephanie Keithly, Novo Nordisk	Rick Pope, Magellan
Robert Pearce, Teva	Jim Kooyman, Sunovion	David Large, BI	Michell Cole, Aetelion
Tracey Gaspen, UCB	Kevin Budt, Merck	Berend Koops, Merck	Susan Zalenski, J&J
Curt Griffith, UCB	Ben Kerner, Merck	Jerry Clewell, Abbott	Eric Blake, Merck
William Dozier, Gilead	Eric Gardner, Vertex	Mike Klaus, Pfizer	Chet Steckler, Purdue
Mary Cook, Purdue	Julie Cleavinger, B&L	Carmen Oliver, Biogen	Debbie King, Amgen
Dave Sproat, BMS	Suzanne Goot, Abbott Laboratories	Jerrica Carter, Biogen	Dean Grath, Pfizer
Janay Jones, Gilead	Scott Edelhauser, Alcon Laboratories	Marne Syemiore, Affymax	Patty Minear, Eli Lilly
Sam Smother, MedImmune	Hank Lavallet, Forest	Jared Lurk, Novartis	

Many names on the sign-in sheet were illegible. Sign in sheet on file for review.

Drug Prior Authorization Committee  
September 20, 2012

<b>Welcome, Introductions and Opening Remarks</b>	<b>Stephen Calloway, RPh, Chair of the Board called the meeting to order.</b> Rhonda Driver announced Tasia Roberts submitted her resignation and her last day will be September 28, 2012. Rhonda also introduced new Senior Office Support Assistant, Marsha Kelly and Senior Office Support Assistant, Jennifer Willmeno. Rhonda stated email meeting notices will be redirected. Pat Bryant introduced new member, David Buchta.
<b>Minutes Approval</b>	Minutes of the June 21, 2012, meeting were reviewed and approved as submitted. <b>Conrad Balcer moved to accept the meeting minutes; Pat Bryant seconded the motion.</b> (See Roll Call Vote)
<b>Pharmacy Program/Budget Update</b>	Andrew Haslag provided a Budget Update. He stated that the fiscal year closed with pharmacy slightly under budget and now working on next year's, Fiscal Year 13 budget. He stated the biggest part in determining where pharmacy will end up is in generic savings; are they going to occur; is it going to be achieved. This is the biggest unknown and will be monitored on a monthly basis. He stated the Fiscal Year 14 budget is due to the governor's office on October 1, 2012. Rhonda Driver stated there are no changes on Health Home program update and she is looking into ways to maximize the 340B pricing into our program. She stated that there will be a presentation in December.
<b>DUR Report</b>	The annual DUR report scheduled to be processed on September 28, 2012. Rhonda stated all items from June were ratified in July and will be implemented October 4, 2012. DUR news letter template in the process.
<b>Old Business</b>	
<b>Implementation Schedule</b>	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The schedule included the items that were discussed in March and April. SNRI and SSRI edits have been ratified and those are schedule to close out the quarter. Schedules may be found on the MHD web page at <a href="http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf">http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf</a>
<b>New Business</b>	
<b>New Drug Review</b>	Rhonda Driver reviewed the new drug products that were identified for the quarter that included April, May, and June of 2012, and the recommended status within the clinical program. <b>Discussion</b> – A listing of products recommended for open access, clinical edit, as a preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all attending. <ul style="list-style-type: none"> <li>• <b>Public Hearing</b> – M. Syemiore, Nephrology Consultant, with Affymax presented information about the product Omontys. James Osborne, Medical Liaison, with GSK presented information about the product Potiga and agreed with the 15 day clinical edit.</li> <li>• <b>Decision</b> – Members voted to accept the new drug recommendations as presented. (See Roll Call Vote)</li> </ul>
<b>PDL Annual Review:</b>	
<b>ACE Inhibitors</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>-No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>

<b>ACE Inhibitors Diuretic Combinations</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>ACE Inhibitor / Calcium Channel Blocker</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Alpha-Glucosidase Inhibitors</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Alzheimer's Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Angiotensin Receptor Blocker</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Angiotensin Receptor Blocker Diuretic Combinations</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Anti-Diabetic Combination Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Antihyperuricemic Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Biguanides</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Bile Salts</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Bone Ossificatin Suppression Agents and Calcitonins</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Cryopyrin Associated Periodic Syndrome (CAPS) Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Direct Renin Inhibitor and</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> </ul>

<b>Combinations</b>	<ul style="list-style-type: none"> <li>• <b>Public Hearing-</b> No comments were entered.</li> <li>• <b>Decision –</b> The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Electrolyte Depleters</b>	<ul style="list-style-type: none"> <li>• <b>Discussion –</b> Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing-</b> No comments were entered.</li> <li>• <b>Decision –</b> The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Fibromyalgia Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion –</b> Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing-</b> Michael Kloos, PharmD, with Pfizer, presented updated information about the product Lyrica and asked the Board to consider placing this drug in the preferred class.</li> <li>• <b>Decision –</b> The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Herpes Antivirals</b>	<ul style="list-style-type: none"> <li>• <b>Discussion –</b> Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing-</b> No comments were entered.</li> <li>• <b>Decision –</b> The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>DMARDS / Immunomodulators</b>	<ul style="list-style-type: none"> <li>• <b>Discussion –</b> Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing-</b> Curt Griffith, Medical Team Member, with UCB, presented updated information about the product Cimzia. There has been a label change with added human data for pregnancy, still category B.</li> <li>• <b>Decision –</b> The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Inhaled Antibiotics</b>	<ul style="list-style-type: none"> <li>• <b>Discussion –</b> Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing-</b> William Dozier, National Account Manager, with Gilead Science, presented information about the product Cayston.</li> <li>• <b>Decision –</b> The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Intranasal Antihistamines</b>	<ul style="list-style-type: none"> <li>• <b>Discussion –</b> Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing-</b> No comments were entered.</li> <li>• <b>Decision –</b> The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Leukotrine Modifiers</b>	<ul style="list-style-type: none"> <li>• <b>Discussion –</b> Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing-</b> No comments were entered.</li> <li>• <b>Decision –</b> The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Niacin Preparations and Combinations</b>	<ul style="list-style-type: none"> <li>• <b>Discussion –</b> Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing-</b> No comments were entered.</li> <li>• <b>Decision –</b> The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Low Sedating Antihistamines</b>	<ul style="list-style-type: none"> <li>• <b>Discussion –</b> Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing-</b> No comments were entered.</li> <li>• <b>Decision –</b> The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Low Sedating Antihistamines / Decongestant Combos</b>	<ul style="list-style-type: none"> <li>• <b>Discussion –</b> Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing-</b> No comments were entered.</li> <li>• <b>Decision –</b> The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Macrolides-Adult / Pediatric</b>	<ul style="list-style-type: none"> <li>• <b>Discussion –</b> Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing-</b> No comments were entered.</li> </ul>

	<ul style="list-style-type: none"> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Meglitinides</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Multiple Sclerosis Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- Jared Lurk, Medical Affairs, with Novartis, presented information about the product Gilenya.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Narcotics: Long Acting</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- Mary Cook, PharmD, Sr. Area Director, Medical Liaison, with Purdue Pharma presented information about Butrans.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Nasal Steroids</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- Jim Kooyman, Medical Science Liaison, with Sunovion, presented information on the product Zetonna. John Mattson, PhD, Medical Science Liaison, with Teva Pharmaceuticals, presented information on the product Qnasl.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>NSAID Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- Jim Boumann, Regional Account Manager, Pfizer, asked the Board to table this class to include topical NSAIDs.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Ophthalmic Antihistamines</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- Jennifer Luth, PhD, Medical Science Liaison, with Bausch &amp; Lomb Pharmaceuticals, presented information on the product Bepreve and Alex.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Ophthalmic Mast Cell Stabilizers</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> –The Committee voted to accept this edit and review the suggestion. (See Roll Call Vote)</li> </ul>
<b>Ophthalmic Prostaglandin Agonists</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Ophthalmic Quinolones</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- Jennifer Luth, PhD, Medical Science Liaison, with Bausch &amp; Lomb Pharmaceuticals, presented information on the product Besivance.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Otic Quinolones</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> </ul>

	<ul style="list-style-type: none"> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Pancreatic Enzymes</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Pulmonary Hypertension Agents – Inhales / Injectable</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Pulmonary Hypertension Agents - Oral</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Quinolones - Systemic</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>2<sup>nd</sup> Generation Sulfonylureas</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Self-Injectable Epinephrine Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Serotonin Receptor Agonists (Triptans)</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Tetracyclines</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Thiazolidinediones</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Topical agents for Psoriasis</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Topical Retinoids</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Topical steroids: Low, Medium, High, Very High</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>

<b>Tramadol-Like Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Ulcerative Colitis Agents – Oral</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Ulcerative Colitis Agents - rectal</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Vaginal antibiotics</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated there is no change recommended for this class.</li> <li>• <b>Public Hearing</b>- No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Preferred Drug List Announcement</b>	A handout of therapeutic categories to be considered for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page. Rick Pope, PharmD, with First Health Services stated the new PDL class schedule will start in March/April meeting with 4 contract periods, each with a renewal and a theme. January/February meetings will include respiratory, ophthalmic, and topical. June/July meeting will include diabetics and endocrines. September/ October meeting will include cardiovascular. December/January meeting will include CNS and neuropathic pain.
<b>Xerox Update</b>	Jennifer Kemp-Cornelius, PharmD, reviewed the call center statistics for short-acting narcotics. Ms. Kemp-Cornelius went over the approval and denial criteria for short-acting narcotics. She also reviewed the per member-per month costs for single agent and combination short-acting narcotics that are most prescribed. Ms. Kemp-Cornelius asked if there were any edits that the Board was interested in looking at utilization for at the next meeting. She stated that her team would look at the psych edits for the December 20, 2012, meeting.
<b>Program Utilization: Top 25 Drugs by Cost</b>	Jennifer Kemp-Cornelius, PharmD, reviewed the Top 25 Drugs by Cost and provided two forms, one showing by Paid Amount and one by Claims.
<b>Call Center Statistics/ CyberAccess Reports</b>	A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity was shared. Ms. Kemp-Cornelius reviewed how many sites/physical locations are trained and have access to CyberAccess and how many prescribers and active users CyberAccess has. She stated that her team is still working on adding psychology and counseling sites. Implementing a messaging system within CyberAccess and the benefits a message system could serve were discussed. Obtaining Home Health prior authorizations through CyberAccess was discussed.
<b>Adjourn</b>	The meeting was adjourned at approximately 2:40 pm. The next meeting of the Drug PA Committee is scheduled for December 20, 2012, and is expected to be held at the Secretary of State Building at 600 West Main Street. Attendees were advised to check the <u>calendar of events</u> on the MHD website for meeting location changes over the next few months. (See attached roll call)

**Roll Call Votes – September 20, 2012**

Member	Minutes	New Drug Review	ACE Inhibitors / ACE Inhibitors Diuretic combinations	ACE Inhibitor / Calcium Channel Blocker / Alpha-Glucosidase Inhibitors	Alzheimer's Agents	Angiotensin Receptor Blocker / Angiotensin Receptor Blocker Diuretic Combinations	Anti-Diabetic Combination Agents	Antihyperuricemic Agents
Conrad Balcer, D.O.	M	M	M	M	Y	S	S	Y
Pat Bryant, Pharm.D.	S	S	S	S	S	Y	M	S
Steven Calloway, R. Ph	Y	Y	Y	Y	Y	Y	Y	Y
Gene Forrester, R. Ph.	Y	Y	Y	Y	M	M	Y	M
Laine Young-Walker, M.D.	A	A	A	A	A	A	A	A

Member	Biguanides	Bile Salts	Bone Ossification Suppression Agents and Cacitonins	Cryopyrin Associated Periodic Syndrome (CAPS) Agents	Direct Renin Inhibitor and Combinations	Electrolyte Depleters	Fibromyalgia Agents
Conrad Balcer, D.O.	M	M	S	S	M	S	S
Pat Bryant, Pharm.D.	Y	Y	M	M	Y	M	Y
Steven Calloway, R. Ph	Y	Y	Y	Y	Y	Y	Y
Gene Forrester, R. Ph.	S	S	Y	Y	S	Y	M
Laine Young-Walker, M.D.	A	A	A	A	A	A	A

Member	Herpes Antivirals	DMARDS / Immunomodulators	Inhaled Antibiotics	Intranasal Antihistamines	Leukotriene Modifiers	Niacin Preparations and Combinations	Low Sedating Antihistamines / Low Sedating Antihistamine / Decongestant
--------	-------------------	---------------------------	---------------------	---------------------------	-----------------------	--------------------------------------	---



							Combos
Conrad Balcer, D.O.	M	Y	M	S	S	M	M
Pat Bryant, Pharm.D.	S	S	Y	Y	M	Y	S
Steven Calloway, R. Ph	Y	M	Y	Y	Y	Y	Y
Gene Forrester, R. Ph.	Y	Y	S	M	Y	S	Y
Laine Young-Walker, M.D.	A	A	A	A	A	A	A

Member	Macrolides-Adult / Pediatric / Meglitinides	Multiple Sclerosis Agents	Narcotics: Long Acting	Nasal Steroids	NSAID Agents	Ophthalmic Antihistamines	Ophthalmic Mast Cell Stabilizers
Conrad Balcer, D.O.	S	M	M	Y	M	M	S
Pat Bryant, Pharm.D.	Y	Y	Y	M	S	S	M
Steven Calloway, R. Ph	Y	Y	Y	Y	Y	Y	Y
Gene Forrester, R. Ph.	M	S	S	S	Y	Y	Y
Laine Young-Walker, M.D.	A	A	A	A	A	A	A

Member	Ophthalmic Prostaglandin Agonists	Ophthalmic Quinolones	Otics Quinolones	Pancreatic Enzymes	Pulmonary Hypertension Agents – Inhaled / Injectable	Pulmonary Hypertension Agents – Orals	Quinolones – Systemic
Conrad Balcer, D.O.	M	M	Y	Y	S	Y	Y
Pat Bryant, Pharm.D.	S	S	M	S	Y	M	M
Steven Calloway, R. Ph	Y	Y	Y	Y	Y	Y	Y
Gene Forrester, R. Ph.	Y	Y	S	M	M	S	S
Laine Young-Walker, M.D.	A	A	A	A	A	A	A

Member	2 <sup>nd</sup> Generation Sulfonyureas	Self-Injectable Epinephrine Agents	Serotonin Receptor Agonists (Triptans)	Tetracyclines	Thiazolidinediones	Topical Agents for Psoriasis	Topical Retinoids
--------	---	------------------------------------	--	---------------	--------------------	------------------------------	-------------------

<b>Conrad Balcer, D.O.</b>	S	S	S	S	S	M	S
<b>Pat Bryant, Pharm.D.</b>	Y	Y	Y	M	M	S	Y
<b>Steven Calloway, R. Ph</b>	Y	Y	Y	Y	Y	Y	Y
<b>Gene Forrester, R. Ph.</b>	M	M	M	Y	Y	Y	M
<b>Laine Young-Walker, M.D.</b>	A	A	A	A	A	A	A

<b>Member</b>	<b>Topical Steroids: Low, Medium, High, Very High</b>	<b>Tramadol-Like Agents</b>	<b>Ulcerative Colitis Agent – Oral / Ulcerative Colitis Agents – Rectal</b>	<b>Vaginal Antibiotics</b>	<b>Adjorn</b>	<b>Executive Session</b>	
<b>Conrad Balcer, D.O.</b>	S	M	M	S	S	S	
<b>Pat Bryant, Pharm.D.</b>	Y	Y	S	M	Y	Y	
<b>Steven Calloway, R. Ph</b>	Y	Y	Y	Y	Y	Y	
<b>Gene Forrester, R. Ph.</b>	M	S	Y	Y	M	M	
<b>Laine Young-Walker, M.D.</b>	A	A	A	A	A	A	A